Home › Funds › Novo Holdings A/S › BBOT

Novo Holdings A/S position in BBOT

BRIDGEBIO ONCOLOGY THERAPEUT · Health Care

Novo Holdings A/S reported holding 2,250,000 shares of BBOT (BRIDGEBIO ONCOLOGY THERAPEUT) in its Q3 2026 13F filing — a position valued at US$9.2M, representing 0.62% of its reported portfolio and ranking #24 among its reported holdings. Novo Holdings A/S has disclosed BBOT holdings in 5 of the last 5 reported quarters, going back to Q3 2025.

Latest position (Q3 2026)2.25M sh
Reported value held$9.22M
Portfolio Weight0.62%
First reportedQ3 2025
Last changeHold
Updated2026-11-17

Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR

How Novo Holdings A/S's BBOT position evolved

Novo Holdings A/S first disclosed a stake in BBOT in Q3 2025 at 1,961,317 shares (US$22.7M). The position peaked in Q4 2025 at 1,961,317 shares, worth US$24.6M. Across 5 filings, Novo Holdings A/S increased the stake 2 time(s), trimmed it 0 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 2,250,000 shares valued at US$9.2M.

Quarter by quarter

QuarterSharesValueChange
Q3 2025 1.96M $22.71M New
Q4 2025 1.96M $24.56M Hold
Q1 2026 2.19M $19.56M Add
Q2 2026 2.25M $17.14M Add
Q3 2026 2.25M $9.22M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About BBOT and 13F data

BBOT (BRIDGEBIO ONCOLOGY THERAPEUT) is a Health Care company. 87 other funds we track also report a position in BBOT — the largest reported positions include Cormorant Asset Management, LP (US$73.3M), Omega Fund Management, LLC (US$13.5M), Alphabet Inc. (US$11.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding BBOT

All BBOT fund holders →

FAQ

How long has Novo Holdings A/S held BBOT?

Novo Holdings A/S has disclosed BBOT holdings in 5 of the last 5 reported quarters, going back to Q3 2025.

What is Novo Holdings A/S's current position in BBOT?

As of Q3 2026, Novo Holdings A/S holds 2.25M shares of BBOT (BRIDGEBIO ONCOLOGY THERAPEUT), valued at $9.22M, representing 0.62% of its reported portfolio and ranking #24.

Has Novo Holdings A/S been buying or selling BBOT?

In the latest 13F filing (Q3 2026), Novo Holdings A/S held unchanged its position in BBOT. The position peaked in Q4 2025 at 1.96M shares.

Which other funds hold BBOT?

Other major institutional holders of BBOT include Cormorant Asset Management, LP, Omega Fund Management, LLC, Alphabet Inc., among 87 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.